Chalcogen Or Nitrogen Attached Directly To Ring Carbon Of The Thiadiazole Ring By Nonionic Bonding Patents (Class 548/135)
  • Publication number: 20030236232
    Abstract: A class of novel benzo(b)thiophene is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Application
    Filed: December 3, 2002
    Publication date: December 25, 2003
    Inventors: Michael Dean Kinnick, Ho-Shen Lin, Michael John Martinelli, John Michael Morin, Michael Enrico Richett
  • Publication number: 20030225076
    Abstract: Diarylanines, such as 5-amide substituted diarylamines of formula (I) or formula (II) wherein A is hydroxy, C1-6 alkoxy, or NR6OR7; X is OR12, NR13R12, or NR14; inhibitors of MEK and are useful in the treatment of a variety of proliferative disease states, such as conditions related to the hyperactivity of MEK, as well as diseases modulated by the MEK cascade.
    Type: Application
    Filed: September 13, 2002
    Publication date: December 4, 2003
    Inventors: Cathlin Biwersi, Haile Tecle, Joseph Scott Warmus
  • Publication number: 20030195238
    Abstract: Compounds of general formula (I): 1
    Type: Application
    Filed: November 8, 2002
    Publication date: October 16, 2003
    Inventors: Ana Martinez Gil, Ana Castro Morera, Maria Concepcion Martin Perez, Mercedes Alonso Cascon, Isabel Dorronsoro Diaz, Francisco Jose Moreno Munoz, Francisco Wandosell Jurado
  • Patent number: 6617339
    Abstract: Compounds of formula (I) as defined herein, or a pharmaceutically acceptable salt, or an in-vivo-hydrolysable ester thereof, are useful as antibacterial agents. Processes for their manufacture and pharmaceutical compositions containing them are described.
    Type: Grant
    Filed: December 5, 2000
    Date of Patent: September 9, 2003
    Assignee: Syngenta Limited
    Inventor: Michael Barry Gravestock
  • Patent number: 6559171
    Abstract: The present invention relates to muscarinic receptor modulators, specifically, 7-oxo-2-azabicyclo[2.2.1]heptanes of formula (I) which are useful for the treatment of various diseases and conditions, for example, Alzheimer's disease, glaucoma, psychosis, particularly schizophrenia or schizophreniform conditions, mania, pain, bipolar disorder, depression, sleeping disorders, epilepsy, gastrointestinal motility disorders, urinary incontinence, and cognition enhancement.
    Type: Grant
    Filed: November 1, 2001
    Date of Patent: May 6, 2003
    Assignee: Eli Lilly and Company
    Inventors: Charles Howard Mitch, Steven James Quimby
  • Patent number: 6537948
    Abstract: The present invention relates to an uracil compound of the formula [I]: [wherein, Q—R3 represents a R3-substituted group of a 5-membered or 6-membered heterocyclic ring having one or two nitrogen selected from the group consisting of moieties represented in the specification (wherein, this heterocyclic ring may be substituted with at least one kind of substituent, Y represents oxygen, sulfur, imino or C1 to C3 alkylimino, R1 represents C1 to C3 alkyl or C1 to C3 haloalkyl, R2 represents C1 to C3 alkyl, R3 represents carboxy C1 to C6 alkyl, C1 to C6 alkoxycarbonyl C1 to C6 alkyl, OR7, SR8, N(R9)R10 or the like, X1 represents halogen, cyano, thiocarbamoyl or nitro, X2 represents hydrogen or halogen. {wherein, each of R7, R8 and R10 independently represents carboxy C1 to C6 alkyl, C1 to C6 alkoxycarbonyl C1 to C6 alkyl, C1 to C6 haloalkoxycarbonyl C1 to C6 alkyl, or the like, and R9 represents hydrogen or C1 to C6 alkyl.}.].
    Type: Grant
    Filed: January 31, 2001
    Date of Patent: March 25, 2003
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: Yoshitomo Tohyama, Yuzuru Sanemitsu
  • Publication number: 20020115697
    Abstract: The present invention relates to therapeutically active azabicyclic compounds, a method of preparing the same and to pharmaceutical or veterinary compositions comprising the compounds. The novel compounds are useful in treating a disease in the central nervous system caused by malfunctioning of the muscarinic cholinergic system.
    Type: Application
    Filed: August 28, 2001
    Publication date: August 22, 2002
    Inventors: Lone Jeppesen, Per Sauerberg
  • Patent number: 6395762
    Abstract: This invention provides compounds of Formula I having the structure wherein, R1, R2, and X are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.
    Type: Grant
    Filed: July 12, 2001
    Date of Patent: May 28, 2002
    Assignee: American Home Products Corporation
    Inventors: William Floyd Fobare, Jill Freymuller
  • Publication number: 20020052510
    Abstract: This invention relates to novel N-linked sulfonamides of N-heterocyclic carboxylic acid and carboxylic acid isosteres, their preparation, and use for treating neurological disorders including physically damaged nerves and neurodegenerative diseases, and for treating alopecia and promoting hair growth.
    Type: Application
    Filed: December 3, 1998
    Publication date: May 2, 2002
    Inventors: GREGORY S. HAMILTON, MARK H. NORMAN, YONG-QIAN WU
  • Publication number: 20020025973
    Abstract: This invention provides compounds of Formula I having the structure 1
    Type: Application
    Filed: July 12, 2001
    Publication date: February 28, 2002
    Applicant: American Home Products Corporation
    Inventors: William F. Fobare, Jill Freymuller
  • Patent number: 6331537
    Abstract: This invention relates to novel N-heteorocyclic carboxylic acids and carboxylic acid isosteres, their preparation and use for treating neurological disorders including physically damaged nerves and neurodengenerative diseases, for treating alopecia and promoting hair growth, for treating vision disorders and/or improving vision, and for treating memory impairment and/or enhancing memory performance by administering such compounds.
    Type: Grant
    Filed: December 2, 1999
    Date of Patent: December 18, 2001
    Assignee: GPI Nil Holdings, Inc.
    Inventors: Gregory S. Hamilton, Mark H. Norman, Yong-Qian Wu
  • Patent number: 6300325
    Abstract: This invention relates to novel benzo-2-triazole substituted compounds, pharmaceutical compositions, processes for their preparation, and use thereof in treating IL-8, GRO&agr;, GRO&bgr;, GRO&ggr; and NAP-2 mediated diseases.
    Type: Grant
    Filed: July 9, 1999
    Date of Patent: October 9, 2001
    Assignee: SmithKline Beecham Corporation
    Inventors: Katherine L. Widdowson, Melvin C. Rutledge
  • Patent number: 6187798
    Abstract: The present invention provides aza-bicyclo[2.2.1]heptane compounds which are useful for modulating a muscarinic receptor.
    Type: Grant
    Filed: June 1, 1999
    Date of Patent: February 13, 2001
    Assignee: Eli Lilly and Company
    Inventors: Leander Merritt, Lone Jeppesen, John S. Ward
  • Patent number: 6130225
    Abstract: The invention relates to novel substituted p-trifluoromethylphenyluracils of the general formula (I) in which R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are each as defined in the description, to a process for their preparation and to their use as herbicides.
    Type: Grant
    Filed: February 2, 1999
    Date of Patent: October 10, 2000
    Assignee: Bayer Aktiengesellschaft
    Inventors: Mark-Wilhelm Drewes, Roland Andree, Markus Dollinger
  • Patent number: 6124312
    Abstract: The present invention provides heterocyclic 2-aza-bicyclo[2.2.1]heptane compounds which are useful for modulating a muscarinic ptor.
    Type: Grant
    Filed: June 1, 1999
    Date of Patent: September 26, 2000
    Assignee: Eli Lilly and Company
    Inventors: Charles H Mitch, Steven J Quimby, Jon K Reel, Celia A Whitesitt
  • Patent number: 6100252
    Type: Grant
    Filed: December 8, 1998
    Date of Patent: August 8, 2000
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Takehiko Naka, Yoshiyuki Inada
  • Patent number: 6069159
    Abstract: The present invention provides heterocyclic compounds which are useful for modulating a muscarinic receptor.
    Type: Grant
    Filed: May 10, 1999
    Date of Patent: May 30, 2000
    Assignee: Eli Lilly and Company
    Inventors: Leander Merritt, Lone Jeppesen, John S Ward
  • Patent number: 6040442
    Abstract: The presently claimed process provides a method for preparing compounds of the formula ##STR1## phosphorous (III) compound and a diester of azodicarboxylate.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: March 21, 2000
    Assignee: Eli Lilly and Company
    Inventors: Leander Merritt, John S. Ward
  • Patent number: 6022868
    Abstract: Disclosed are compounds of formula (I) selected from the following ##STR1## wherein Y is ##STR2## and wherein A, B, C, D, R, k, m, n, o, p, s, t and u are as defined in the specification. These compounds are useful in treating diseases in the central nervous system related to malfunctioning of the nicotinic cholinergic system.
    Type: Grant
    Filed: December 19, 1997
    Date of Patent: February 8, 2000
    Assignee: Novo Nordisk Als
    Inventors: Preben Houlberg Olesen, John Bondo Hansen
  • Patent number: 6015813
    Abstract: The present invention relates to therapeutically active azabicyclic compounds of formula I ##STR1## wherein X, R.sup.1, R.sup.2, R.sup.3, Ar, m and n are defined in the description, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating a disease in the central nervous system caused by malfunctioning of the muscarinic cholinergic system.
    Type: Grant
    Filed: April 8, 1998
    Date of Patent: January 18, 2000
    Assignee: Novo Nordisk A/S
    Inventors: Lone Jeppesen, Per Sauerberg
  • Patent number: 5977129
    Abstract: The present invention relates to compounds of formula I: whereinone or both G is an azacyclic ring of formula II: ##STR1## and Z is oxygen or sulfur and the remaining variables are as defined in the specification. The compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease, severe painful conditions and glaucoma.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: November 2, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Preben H. Olesen, Per Sauerberg
  • Patent number: 5972978
    Abstract: The present invention relates to novel organic compounds, to methods for their preparation, to compositions containing them, to their use for treatment of human and animal disorders, to their use for purification of proteins or glycoproteins, and to their use in diagnosis. The invention relates to modulation of the activity of molecules with phospho-tyrosine recognition units, including protein tyrosine phosphatases (PTPases) and proteins with Src-homology-2 domains, in in vitro systems, microorganisms, eukaryotic cells, whole animals and human beings. The novel organic compounds are compounds of formula (I)(L).sub.n --Ar.sub.1 --R.sub.1 A (I)wherein(L).sub.n, n, Ar.sub.1, R.sub.1 and A are as defined in the application.
    Type: Grant
    Filed: February 19, 1999
    Date of Patent: October 26, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Henrik Sune Andersen, Niels Peter Hundahl Moller, Peter Madsen
  • Patent number: 5948916
    Abstract: Novel arylthiadiazole derivatives and salts thereof useful for preventing and treating human viral infection and a novel virucide which contains the arylthiadiazole derivative or a salt thereof are provided. N,N-dimethyl ?3-(3-(amino-2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl! carbamate or its salt, and virucide containing the same as an effective component.
    Type: Grant
    Filed: June 9, 1997
    Date of Patent: September 7, 1999
    Assignee: Rational Drug Design Laboratories
    Inventors: Katsushi Ijichi, Shiro Shigeta, Masanori Baba, Masatoshi Fujiwara, Tomoyuki Yokota, Hiromitsu Takayama, Shin-ichiro Sakai, Yasuaki Hanasaki, Teruhiko Ide, Hiroyuki Watanabe, Kimio Katsuura
  • Patent number: 5929247
    Abstract: The present invention relates to therapeutically active azacyclic or azabicyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system caused by malfunctioning of the muscarinic cholinergic system.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 27, 1999
    Assignee: Eli Lilly and Company
    Inventors: Charles A. Alt, Leander Merritt, Gary A. Rhodes, Roger L. Robey, Eldon E. Van Meter, John S. Ward, Charles H. Mitch
  • Patent number: 5919809
    Abstract: This invention relates to novel 3-substituted-2-oxindole derivatives of the formula ##STR1## and the pharmaceutically-acceptable salts thereof which are inhibitors of prostaglandin H.sub.2 synthase, 5-lipoxygenase and interleukin-1 biosynthesis. The compounds of the invention are useful as inhibitors of prostaglandin H.sub.2 synthase and interleukin-1 biosynthesis, per se, and as analgesic, antiinflammatory and antiarthritic agents in the treatment of chronic inflammatory diseases. This invention also relates to pharmaceutical compositions comprising said 3-substituted-2-oxindole derivatives; to methods of inhibiting prostaglandin H.sub.2 synthase and biosynthesis of interleukin-1; and to treating chronic inflammatory diseases in a mammal with said compounds. Further, this invention relates to certain novel carboxylic acids useful as intermediates in the preparation of the 3-substituted-2-oxindole derivatives of this invention and to a process for the preparation of the 3-substituted-2-oxindole derivatives.
    Type: Grant
    Filed: November 4, 1993
    Date of Patent: July 6, 1999
    Assignee: Pfizer Inc.
    Inventors: Frederick J. Ehrgott, Carl J. Goddard, Gary R. Schulte
  • Patent number: 5914338
    Abstract: The present invention relates to therapeutically active azatricyclic compounds of formula I ##STR1## a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating a disease in the central nervous system caused by malfunctioning of the muscarinic cholinergic system.
    Type: Grant
    Filed: April 1, 1997
    Date of Patent: June 22, 1999
    Assignee: Novo Nordisk
    Inventors: Lone Jeppesen, Preben H. Olesen, Per Sauerberg
  • Patent number: 5821371
    Abstract: The present invention relates to therapeutically active azacyclic or azabicyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system caused by malfunctioning of the muscarinic cholinergic system.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 13, 1998
    Assignee: Eli Lilly and Comany
    Inventors: Charles A. Alt, Leander Merritt, Gary A. Rhodes, Roger L. Robey, Eldon E. Van Meter, John S. Ward, Charles H. Mitch
  • Patent number: 5821370
    Abstract: The present invention relates to therapeutically active azacyclic or azabicyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system caused by malfunctioning of the muscarinic cholinergic system.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 13, 1998
    Assignee: Eli Lilly and Company
    Inventors: Charles A. Alt, Leander Merritt, Gary A. Rhodes, Roger L. Robey, Eldon E. Van Meter, John S. Ward
  • Patent number: 5767280
    Abstract: The present invention relates to a process for making intermediates useful for preparing therapeutically active azacyclic or azabicyclic compounds.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: June 16, 1998
    Assignee: Eli Lilly and Company
    Inventors: Roger L. Robey, John S. Ward
  • Patent number: 5760222
    Abstract: Bleaches, a method for bleaching substrates using these materials and detergent compositions containing same are reported. The bleaches are thiadiazole dioxide derived mono- and di- oxaziridines. Substrates such as fabrics may be bleached in an aqueous solution containing the oxaziridine.
    Type: Grant
    Filed: December 3, 1996
    Date of Patent: June 2, 1998
    Assignee: Lever Brothers Company, Division of Conopco, Inc.
    Inventor: Janet Lynn Coope
  • Patent number: 5747514
    Abstract: The present invention relates to therapeutically active hydroxamic acid and carboxylic acid derivatives, to processes for their preparation, to pharmaceutical compositions containing them, and to the use of such compounds in medicine. In particular, the compounds are inhibitors of metalloproteinases involved in tissue degradation, and in addition are inhibitors of the release of tumor necrosis factor from cells.
    Type: Grant
    Filed: July 19, 1996
    Date of Patent: May 5, 1998
    Assignee: British Biotech Pharmaceuticals Limited
    Inventors: Raymond Paul Beckett, Mark Whittaker, Andrew Miller, Fionna Mitchell Martin
  • Patent number: 5731441
    Abstract: The invention provides hydroxamic acid derivatives of the general formula ##STR1## wherein R.sup.1 represents cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; R.sup.2 represents a saturated 5- to 8-membered monocyclic or bridged N-heterocyclic ring, which N-heterocyclic ring is attached via the N atom and when it is monocyclic, optionally contains NR.sup.4, O, S, SO or SO.sub.2 as a ring member and/or is optionally substituted on one or more C atoms by hydroxy, lower alkyl, lower alkoxy, oxo, ketalized oxo, amino, mono(lower alkyl)amino, di(lower alkyl)amino,carboxy, lower alkoxycarbonyl, hydroxy-methyl, lower alkoxymethyl, carbamoyl, mono(lower alkyl)-carbamoyl, di(lower alkyl)carbamoyl or hydroxyimino; R.sup.3 represents a 5- or 6-membered N-heterocyclic ring which (a) is attached via the N atom, (b) optionally contains N, O and/or S, SO or SO.sub.
    Type: Grant
    Filed: October 29, 1996
    Date of Patent: March 24, 1998
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Michael John Broadhurst, Paul Anthony Brown, William Henry Johnson
  • Patent number: 5703065
    Abstract: The invention relates to compounds of the formula ##STR1## and to pharmaceutically acceptable salts thereof, wherein A, W, P, R.sup.3, Q and R.sup.1 are as defined herein. The compounds of formula I, and pharmaceutically acceptable salts thereof, are substance P antagonists and as such are useful in the treament of various inflammatory and central nervous system disorders.
    Type: Grant
    Filed: May 7, 1996
    Date of Patent: December 30, 1997
    Assignee: Pfizer Inc.
    Inventor: Harry R. Howard, Jr.
  • Patent number: 5675023
    Abstract: The present invention relates to a chromone derivative and an aldose reductase inhibitor comprising said compound as efective component, which is represented by the following formula: ##STR1## wherein R.sub.1 and R.sub.2 each represent a lower alkyl group, etc., R.sub.3 represents an oxygen atom, a sulfur atom, etc., R.sub.7 represents a phenyl group substituted or not substituted, etc., and R represents a hydrogen atom or a lower alkoxy group. The present compounds exhibit superior inhititory action on aldose reductase and are useful for the treatment of various complications of diseases in diabetes, such as cataract, retinopathy, keratopathy, nephropathy, and neuropathy.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 7, 1997
    Assignee: Tsumura & Co.
    Inventors: Yasushi Igarashi, Takuji Yamaguchi, Yoshimitsu Ogawa, Mika Tomita, Hiroko Hayashi, Toshitsugu Sato, Kunio Hosaka
  • Patent number: 5674894
    Abstract: The current invention discloses novel amidine derivatives with nitric oxide donating property that can inhibit platelet aggregation and promote vasodilation in a single compound.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: October 7, 1997
    Assignee: G.D. Searle & Co.
    Inventors: Mark G. Currie, Foe S. Tjoeng, Mark E. Zupec
  • Patent number: 5672709
    Abstract: The present invention relates to therapeutically active azacyclic or azabicyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system caused by malfunctioning of the muscarinic cholinergic system.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 30, 1997
    Assignee: Eli Lilly and Company
    Inventors: Charles A. Alt, Leander Merritt, Gary A. Rhodes, Roger L. Robey, Eldon E. Van Meter, John S. Ward, Charles H. Mitch
  • Patent number: 5665745
    Abstract: The present invention relates to therapeutically active azacyclic or azabicyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system caused by malfunctioning of the muscarinic cholinergic system.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 9, 1997
    Assignee: Eli Lilly and Company
    Inventors: Charles A. Alt, Leander Merritt, Gary A. Rhodes, Roger L. Robey, Eldon E. Van Meter, John S. Ward, Charles H. Mitch
  • Patent number: 5661165
    Abstract: Disclosed are ((4-phenyl-1,2,5--thiadiazol-3-yl)oxy)methyl ester thiocyanic acid compounds corresponding to the formula: ##STR1## wherein X represents --Br, --Cl, --F, --CF.sub.3, --OCF.sub.3, --CN, C.sub.1 -C.sub.7 straight or branched chain alkyl, C.sub.1 -C.sub.7 straight or branched chain alkoxy or --COOR wherein R is --H or C.sub.1 -C.sub.7 straight or branched chain alkyl and n is an integer of from 0-5.These compounds have been found to exhibit antimicrobial and marine antifouling activity in industrial and commercial applications and compositions containing these compounds are so employed.
    Type: Grant
    Filed: July 10, 1996
    Date of Patent: August 26, 1997
    Assignee: The Dow Chemical Company
    Inventors: Ravi B. Shankar, R. Garth Pews, Duane R. Romer
  • Patent number: 5650419
    Abstract: Described herein are compounds of the formula; ##STR1## wherein: Thi is a unsubstituted or substituted thiadiazolyl;Y is an alkylene bridge of 3-9 carbon atoms;R.sub.1 and R.sub.2 are each independently chosen from hydrogen, halo, alkyl, alkenyl, amino, alkylthio, hydroxy, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, alkoxy, nitro, carboxy, alkoxylcarbonyl, dialkylaminoalkyl, alkylaminoalkyl, aminoalkyl, difluoromethyl, trifluoromethyl or cyano;R.sub.3 is alkoxycarbonyl, substituted or unsubstituted phenyl, alkyltetrazolyl or a substituted or unsubstituted imidazolyl, dihydroimidazolyl, pyrazolyl, furyl, thiazolyl or thienyl or a pharmaceutically acceptable salt thereof are effective antipicornaviral agents.
    Type: Grant
    Filed: August 30, 1996
    Date of Patent: July 22, 1997
    Assignee: Sanofi, S.A.
    Inventors: David J. Aldous, Thomas R. Bailey, Guy Dominic Diana, Theodore J. Nitz
  • Patent number: 5646289
    Abstract: The present invention relates to therapeutically active azacyclic or azabicyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system caused by malfunctioning of the muscarinic cholinergic system.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 8, 1997
    Assignee: Eli Lilly and Company
    Inventors: Charles A. Alt, Leander Merritt, Gary A. Rhodes, Roger L. Robey, Eldon E. Van Meter, John S. Ward, Charles H. Mitch
  • Patent number: 5614535
    Abstract: Compounds of the formula I ##STR1## in which R.sup.1 and X have the meanings herein defined, their physiologically unobjectionable salts and/or solvates inhibit the binding of fibrinogen to the corresponding receptor and can be employed for the treatment of thromboses, osteoporosis, tumoral diseases, apoplexy, cardiac infarction, inflammations, arteriosclerosis and osteolytic disorders.
    Type: Grant
    Filed: August 18, 1995
    Date of Patent: March 25, 1997
    Assignee: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Horst Juraszyk, Joachim Gante, Hanns Wurziger, Sabine Bernotat-Danielowski, Guido Melzer
  • Patent number: 5589439
    Abstract: Herbicidal novel tetrazolinone derivatives of the formula: ##STR1## wherein R.sup.1 is alkyl, haloalkyl, cycloalkyl, alkenyl, haloalkenyl, alkynyl, alkoxy or phenyl which is optionally substituted, andR.sup.2 is alkyl, haloalkyl, cycloalkyl, alkenyl, haloalkenyl, alkynyl, alkoxy or phenyl which is optionally substituted, orR.sup.1 and R.sup.2 form, together with the nitrogen atom to which R.sup.1 and R.sup.2 are bonded, a 5- or 6-membered heterocyclic ring, optionally fused to a carbocyclic ring optionally and independently substituted by C.sub.1-4 alkyl, andR.sup.3 is a 5-membered heterocyclic radical containing at least one hereto atom selected from the group consisting of nitrogen, oxygen, and sulfur, optionally substituted by at least one substitutent selected from the group consisting of halogen, benzyl, phenyl, halogen-substituted phenyl, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 haloalkyl, C.sub.1-4 haloalkoxy, C.sub.1-4 alkylthio, C.sub.1-4 alkyl-sulfonyl and C.sub.
    Type: Grant
    Filed: July 28, 1995
    Date of Patent: December 31, 1996
    Assignee: Nihon Bayer Agrochem K.K.
    Inventors: Toshio Goto, Koichi Moriya, Fritz Maurer, Seishi Ito, Katsuaki Wada, Kazuhiro Ukawa, Ryo Watanabe, Asami Ito, Natsuko Minegishi
  • Patent number: 5578634
    Abstract: A class of novel 1H-indole-3-acetic acid hydrazides is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids (e.g., arachidonic acid) for treatment of conditions such as septic shock.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: November 26, 1996
    Assignee: Eli Lilly and Company
    Inventors: Nicholas J. Bach, Robert D. Dillard, Susan E. Draheim, Robert B. Hermann, Richard W. Schevitz
  • Patent number: 5563159
    Abstract: There is disclosed a dithiocarbonimide derivative of the formula: ##STR1## wherein B is a C.sub.1 -C.sub.6 alkyl group; X is an NH group or an oxygen atom and Y is a nitrogen atom or a CH group, A is a phenyl group, a heterocyclic group, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a bicycloalkyl group or a tricycloalkyl group, all of which may be substituted. Also disclosed are a fungicidal/insecticidal/acaricidal agent containing the dithiocarbonimide derivative as an active ingredient, an intermediate for use in the production of the dithiocarbonimide derivative, and a process for producing the dithiocarbonimide derivative from the intermediate.
    Type: Grant
    Filed: December 2, 1994
    Date of Patent: October 8, 1996
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: Tomoyuki Kusaba, Tadashi Ohsumi, Tsuguhiro Katoh, Makoto Fujimura, Norio Kimura, Kazuya Ujihara, Kimitoshi Umeda
  • Patent number: 5556909
    Abstract: Substituted 2-arylcarbonyloxymethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives, pharmaceutical compositions containing them and methods for the treatment of degenerative diseases utilizing them.
    Type: Grant
    Filed: December 2, 1994
    Date of Patent: September 17, 1996
    Assignee: Sanofi Winthrop Inc.
    Inventor: Ranjit C. Desai
  • Patent number: 5554633
    Abstract: Compounds of formula (I), and salts and prodrugs thereof, wherein Q is optionally substituted phenyl or benzhydryl; X and Y are each H or together form a group=O; Z is O, S or NR.sup.9, where R.sup.9 is H or C.sub.1-6 alkyl; R.sup.1 represents H or C.sub.1-6 alkyl; R.sup.2 represents C.sub.1-6 alkyl substituted by CONR.sup.7 (CH.sub.2).sub.p R.sup.8 (where R.sup.7 is H or C.sub.1-6 alkyl, R.sup.8 is optionally substituted heteroaryl and p is 0, 1, 2, 3, 4, 5 or 6); R.sup.3 represents H, C.sub.1-6 alkyl or C.sub.2-6 alkynyl; R.sup.4 represents H, C.sub.1-6 alkyl or optionally substitute phenyl; R.sup.5 represents optionally substituted phenyl; R.sup.6 is H or C.sub.1-6 alkyl; and q is 0, 1, 2 or 3; are tachykinin antagonists useful in therapy.
    Type: Grant
    Filed: January 27, 1995
    Date of Patent: September 10, 1996
    Assignee: Merck, Sharp & Dohme, Ltd.
    Inventor: Martin R. Teall
  • Patent number: 5550139
    Abstract: Isothiazolidin-3-one-1,1 dioxide, 3-oxo-1,2,5-thiadiazolidine-1,1,-dioxide and derivatives thereof, reduce or inhibit the activity of serine proteases. Such compounds are useful as anti-inflammatory and anti-metastatic agents.
    Type: Grant
    Filed: January 3, 1994
    Date of Patent: August 27, 1996
    Assignee: The Wichita State University
    Inventor: William C. Groutas
  • Patent number: 5547920
    Abstract: Thiadiazole derivatives with excellent herbicidal effectiveness, wide herbicidal spectrum and excellent selectivity are disclosed. The thiadiazole derivatives are represented by one of the formula [I]14 [IV].
    Type: Grant
    Filed: June 28, 1994
    Date of Patent: August 20, 1996
    Assignee: Tosoh Corporation
    Inventors: Yasuaki Hanasaki, Kazuaki Tsukuda, Hiroyuki Watanabe, Kenji Tsuzuki, Mitsuyuki Murakami, Noritoshi Niimi
  • Patent number: 5527813
    Abstract: The present invention relates to therapeutically active azabicyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease, severe painful conditions and glaucoma.
    Type: Grant
    Filed: March 2, 1994
    Date of Patent: June 18, 1996
    Assignee: Novo Nordisk A/S
    Inventors: Per Sauerberg, Preben H. Olesen
  • Patent number: 5523312
    Abstract: Disclosed herein are compounds and pharmaceutical compositions useful for combating picornaviruses and preventing or treating picornaviral infections. The compounds have the formula: ##STR1## wherein Het.sub.1 is chosen from the group consisting of oxazolyl, isoxazolyl, oxadiazolyl;Y is an alkylene bridge of 3 to 9 carbon atoms;Het.sub.2 is benzofuranyl or indolyl;R.sub.1 and R.sub.2 are each independently chosen from hydrogen, halo, acetyl, alkyl, alkenyl, amino, alkylthio, hydroxy, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, alkylsulfinyl alkyl, alkylsulfonylalkyl, alkoxy, nitro, carboxy, alkoxycarbonyl, dialkylaminoalkyl, alkylaminoalkyl, aminoalkyl, difluoromethyl, trifluromethyl, or cyano; andR.sub.3 is oxazolyl, oxadiazolyl, isoxazolyl or any of these substituted with alkyl, halo, alkoxyalkyl, cycloalkyl, haloalkyl, hydroxyalkyl, alkoxy, hydroxy, furyl, thienyl, or fluoroalkyl;the N-oxide thereof or a pharmaceutically acceptable acid addition salt thereof.
    Type: Grant
    Filed: September 27, 1994
    Date of Patent: June 4, 1996
    Assignee: Sterling Winthrop Inc.
    Inventors: David J. Aldous, Thomas R. Bailey, Guy D. Diana, Gee-Hong Kuo, Theodore J. Nitz, Michael Reuman